pnht_10q.htm

0001640334-19-001089.txt : 20190607 0001640334-19-001089.hdr.sgml : 20190607 20190607171601 ACCESSION NUMBER: 0001640334-19-001089 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 28 CONFORMED PERIOD OF REPORT: 20190430 FILED AS OF DATE: 20190607 DATE AS OF CHANGE: 20190607 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PANAMERA HEALTHCARE Corp CENTRAL INDEX KEY: 0001620749 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MANAGEMENT CONSULTING SERVICES [8742] IRS NUMBER: 465707326 STATE OF INCORPORATION: NV FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55569 FILM NUMBER: 19886844 BUSINESS ADDRESS: STREET 1: 4180 ORCHARD HILL DRIVE CITY: EDMOND STATE: OK ZIP: 73025 BUSINESS PHONE: 4054135735 MAIL ADDRESS: STREET 1: 4180 ORCHARD HILL DRIVE CITY: EDMOND STATE: OK ZIP: 73025 10-Q 1 pnht_10q.htm FORM 10-Q pnht_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended April 30, 2019

or

¨
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____________ to _____________

Commission File Number 000-55569

PANAMERA HEALTHCARE CORPORATION

(Exact name of registrant as specified in its charter)

Nevada

46-5707326

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

4180 Orchard Hill Drive, Edmond, OK

73025

(Address of principal executive offices)

(Zip Code)

(405) 413-5735

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
None		None		None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x YES ¨ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x YES ¨ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) x YES ¨ NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

17,990,000 shares of common stock issued and outstanding as of June 5, 2019

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	9
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	13
Item 4.	Controls and Procedures	14

PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	15
Item 1A.	Risk Factors	15
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	15
Item 3.	Defaults Upon Senior Securities	15
Item 4.	Mine Safety Disclosures	15
Item 5.	Other Information	15
Item 6.	Exhibits	16
SIGNATURES		17

2

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

PANAMERA HEALTHCARE CORPORATION

Balance Sheets

(Unaudited)

	April 30,			July 31,
	2019			2018
ASSETS
Current Assets
Cash and cash equivalents	$	1,602		$	4,180
Total Current Assets		1,602			4,180

TOTAL ASSETS	$	1,602		$	4,180

LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	-		$	7,999
Accrued interest - related party		5,228			2,734
Due to related party		80,101			53,101
Total Current Liabilities		85,329			63,834

TOTAL LIABILITIES		85,329			63,834

Stockholders’ Deficit
Preferred stock: 50,000,000 authorized; $0.0001 par value no shares issued and outstanding		-			-
Common stock: 150,000,000 authorized; $0.0001 par value 17,990,000 shares issued and outstanding		1,799			1,799
Additional paid in capital		145,750			145,750
Accumulated deficit		(231,276	)		(207,203	)
Total Stockholders’ Deficit		(83,727	)		(59,654	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	1,602		$	4,180

The accompanying notes to the unaudited financial statements are an integral part of these statements.

3

Table of Contents

PANAMERA HEALTHCARE CORPORATION

Statements of Operations

(Unaudited)

	For the						For the
	Three Months Ended						Nine Months Ended
	April 30,						April 30,
	2019			2018			2019			2018
Operating Expenses
Professional fees	$	4,307		$	5,025		$	20,908		$	22,640
General and administration expenses		232			336			670			1,056
Total operating expenses		4,539			5,361			21,578			23,696

Net loss from operations		(4,539	)		(5,361	)		(21,578	)		(23,696	)

Other expense
Interest expense		(911	)		(523	)		(2,495	)		(1,496	)
Total other expense		(911	)		(523	)		(2,495	)		(1,496	)

Net loss before taxes		(5,450	)		(5,884	)		(24,073	)		(25,192	)

Income tax benefit		-			-			-			-

Net loss	$	(5,450	)	$	(5,884	)	$	(24,073	)	$	(25,192	)

Basic and diluted loss per common share	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)

Weighted average number of common shares outstanding, basic and diluted		17,990,000			17,990,000			17,990,000			17,990,000

The accompanying notes to the unaudited financial statements are an integral part of these statements.

4

Table of Contents

PANAMERA HEALTHCARE CORPORATION

Statements of Changes in Stockholders’ Deficit

(Unaudited)

For the Nine Months Ended April 30, 2019

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, July 31, 2018		17,990,000	$	1,799	$	145,750	$	(207,203	)	$	(59,654	)

Net loss		-		-		-		(12,055	)		(12,055	)
Balance, October 31, 2018		17,990,000		1,799		145,750		(219,258	)		(71,709	)

Net loss		-		-		-		(6,568	)		(6,568	)
Balance, January 31, 2019		17,990,000		1,799		145,750		(225,826	)		(78,277	)

Net loss		-		-		-		(5,450	)		(5,450	)
Balance, April 30, 2019		17,990,000	$	1,799	$	145,750	$	(231,276	)	$	(83,727	)

For the Nine Months Ended April 30, 2018

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, July 31, 2017		17,990,000	$	1,799	$	145,750	$	(176,900	)	$	(29,351	)

Net loss		-		-		-		(12,795	)		(12,795	)
Balance, October 31, 2017		17,990,000		1,799		145,750		(189,695	)		(42,146	)

Net loss		-		-		-		(6,513	)		(6,513	)
Balance, January 31, 2018		17,990,000		1,799		145,750		(196,208	)		(48,659	)

Net loss		-		-		-		(5,884	)		(5,884	)
Balance, April 30, 2018		17,990,000	$	1,799	$	145,750	$	(202,092	)	$	(54,543	)

The accompanying notes to the unaudited financial statements are an integral part of these statements.

5

Table of Contents

PANAMERA HEALTHCARE CORPORATION

Statements of Cash Flows

(Unaudited)

	For the
	Nine Months Ended
	April 30,
	2019			2018

CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(24,073	)	$	(25,192	)
Changes in operating assets and liabilities:
Accounts payable		(7,999	)		5,271
Accrued interest - related party		2,494			1,497
Net Cash Used In Operating Activities		(29,578	)		(18,424	)

CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from related party loans		27,000			5,000
Net Cash Provided by Financing Activities		27,000			5,000

Net change in cash and cash equivalents		(2,578	)		(13,424	)
Cash and cash equivalents, beginning of period		4,180			13,460
Cash and cash equivalents, end of period	$	1,602		$	36

Supplemental cash flow information
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-

The accompanying notes to the unaudited financial statements are an integral part of these statements.

6

Table of Contents

PANAMERA HEALTHCARE CORPORATION

Notes to the Unaudited Interim Financial Statements

April 30, 2019

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

Panamera Healthcare Corporation (the “Company”) is a Nevada corporation incorporated on May 20, 2014. It is based in Oklahoma City, OK, USA. The accounting and reporting policies of the Company conform to accounting principles generally accepted in the United States of America, and the Company’s fiscal year end is July 31.

The Company intends to offer management and consulting services to healthcare organizations that are increasingly facing various stresses including financial, organizational, and information technology challenges. To date, the Company’s activities have been limited to its formation and the raising of equity capital.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.

In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K, for the year ended July 31, 2018, as filed with the SEC on October 19, 2018.

NOTE 3 - GOING CONCERN

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of April 30, 2019, the Company has a loss from operations, an accumulated deficit and has not earned any revenues. The Company intends to fund operations through equity financing arrangements and related party advances, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2019

The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings.

These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

7

Table of Contents

NOTE 4 - RELATED PARTY TRANSACTIONS

Note Payable

On July 15, 2014, a corporation controlled by an officer and director committed $75,000 Promissory Note in the form of an unsecured line of credit. Any unpaid balance was due December 31, 2015. On April 15, 2019, the line of credit increased to $100,000 and was extended to December 31, 2019, at an annual interest rate of 5% and may be prepaid without penalty. The Company concluded the note modification was not a significant change and is not treating it as an extinguishment. During the nine months ended April 30, 2019, the Company borrowed $27,000 and repayments under the line of credit to the Company were made in the amount of $0. As of April 30, 2019, the Company was obligated, for this interest bearing loan with a balance of $80,101 and accrued interest of $5,228. The Company plans to pay the loan and interest back as cash flows become available. The remaining balance available under the line of credit is $19,899 as of April 30, 2019. For the nine months ended April 30, 2019 and 2018, the Company paid $0 and $0, respectively, in interest on this note payable.

Other

The Company does not own or lease property or lease office space. The office space used by the Company was arranged by the founder, who is also the CEO and President, of the Company to use at no charge.

8

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our unaudited consolidated financial statements are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in United States dollars and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Panamera Healthcare Corporation, unless otherwise indicated.

General Overview

We were incorporated under the laws of the State of Nevada on May 20, 2014. We intend to offer management and consulting services to healthcare organizations. We intend to focus on ambulatory surgical centers (ASCs) that currently have an incentive to be acquired by hospitals in order to increase compensation levels. We believe the short term strategy of converting to hospital based compensation is not sustainable because fundamental changes in the way healthcare is being provided are being undertaken by both government and private insurance carriers. The demographics of an aging population also mandate such changes to avoid economic disruption, healthcare rationing or unsustainable taxation.

Our address is 4180 Orchard Hill Drive, Edmond, OK 73025. Our telephone number is (405) 413-5735. Our corporate website is www.panamerahealth.com.

We have not ever declared bankruptcy, been in receivership, or involved in any kind of legal proceeding.

The following discussion should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this annual report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to those discussed below and elsewhere in this report. Our unaudited financial statements are stated in United States Dollars and are prepared in accordance with United States Generally Accepted Accounting Principles.

Plan of Operations and Cash Requirements

We intend to offer management and consulting services to healthcare organizations. We intend to devote our marketing efforts toward identifying ambulatory surgical centers (ASC) that currently have an incentive to be acquired by hospitals in order to increase compensation levels. We intend to reorganize ASCs and consolidate several such centers into larger entities that can immediately take advantage of higher reimbursement rates permitted by the reorganization. At the same time, we expect to institute the necessary medical records and management systems to make the transition to value based compensation.

9

Table of Contents

Cash Requirements

We have incurred recurring losses to date. Our financial statements have been prepared assuming that we will continue as a going concern and, accordingly, do not include adjustments relating to the recoverability and realization of assets and classification of liabilities that might be necessary should we be unable to continue in operation. We expect we will require additional capital to meet our long-term operating requirements. We expect to raise additional capital through equity financing arrangements,

Our net loss for the nine months ended April 30, 2019, was $24,073 compared to a net loss of $25,192 for the nine months ended April 30, 2018.

During the nine months ended April 30, 2019, we incurred operating expenses of $21,578 compared to $23,696 incurred during the nine months ended April 30, 2018.

As of April 30, 2019, our current assets were $1,602 compared to $4,180 in current assets at July 31, 2018. As of April 30, 2019, our current liabilities were $85,329 compared to $63,834 in current liabilities at July 31, 2018.

Stockholders’ deficit was $83,727 as of April 30, 2019 compared to $59,654 as of July 31, 2018

Results of Operations for the three months ended April 30, 2019 and 2018

The following tables provide selected financial data about our company as of the three months ended April 30, 2019.

	Three Months Ended
	April 30,
	2019		2018		Changes ($)
Operating expenses	$	4,539	$	5,361	$	(822	)
Interest expense	$	911	$	523	$	388
Net loss	$	5,450	$	5,884	$	(434	)

During the three months ended April 30, 2019 and 2018, no revenues were recorded.

Net loss was $5,450 for the three months ended April 30, 2019, and $5,884 for the three months ended April 30, 2018. The decrease in net loss is mainly due to decrease in operating expense as compared to 2018.

Operating expenses for the three months ended April 30, 2019 and 2018 were $4,539 and $5,361, respectively. The operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) and general and administrative expenses. Professional fees for the three months ended April 30, 2019, was $4,307 compared to $5,025 for the same period ended April 30, 2018. General and administration expenses decreased by $104, to $232 for the three months ended April 30, 2019, from $336 for the three months ended April 30, 2018.

Interest expenses represent interest expense to a related party on funds advanced to the Company.

10

Table of Contents

Results of Operations for the nine months ended April 30, 2019 and 2018

The following table provides selected financial data about our company as of the nine months ended April 30, 2019 and 2018.

	Nine Months Ended
	April 30,
	2019		2018		Changes ($)
Operating expenses	$	21,578	$	23,696	$	(2,118	)
Interest expense	$	2,495	$	1,496	$	999
Net loss	$	24,073	$	25,192	$	(1,119	)

During the nine months ended April 30, 2019 and 2018, no revenues were recorded.

We had a net loss of $24,073 for the nine months ended April 30, 2019, and $25,192 for the same period ended April 30, 2018. The decrease in net loss of $1,119, was primarily due to decrease in operating expenses of $2,118 and offset by an increase in interest expenses of $999.

Operating expenses for the nine months ended April 30, 2019 and 2018 were $21,578 and $23,696, respectively. The operating expenses were primarily attributed to professional fees for maintaining reporting status with the Securities and Exchange Commission (“SEC”) and general and administrative expenses. Professional fees for the nine months ended April 30, 2019, was $20,908 compared to $22,640 for the same period ended April 30, 2018. General and administration expenses decreased by $386 to $670 for the nine months ended April 30, 2019, from $1,056 for the nine months ended April 30, 2018.

Interest expenses represent interest expense to a related party on funds advanced to the Company.

Balance Sheet Data:

	April 30, 2019		July 31, 2018		Changes ($)
Cash	$	1,602	$	4,180	$	(2,578	)
Working capital deficiency	$	83,727	$	59,654	$	24,073
Total assets	$	1,602	$	4,180	$	(2,578	)
Total liabilities	$	85,329	$	63,834	$	21,495
Total stockholders’ deficit	$	83,727	$	59,654	$	24,073

As at April 30, 2019, our current assets were $1,602, and our current liabilities were $85,329 which resulted in working capital deficiency of $83,727. As of April 30, 2019, current assets were comprised of $1,602 in cash, compared to $4,180 in cash as of July 31, 2018. As of April 30, 2019, current liabilities were comprised of $0 in accounts payable and $85,329 in due to related parties and accrued interest, compared to $7,999 in accounts payable and $55,835 due to related party and accrued interest as of July 31, 2018.

As of April 30, 2019, our working capital deficiency increased by $24,073 from $59,654 on July 31, 2018, to $83,727 on April 30, 2019, primarily due to an increase in current liabilities of $21,495.

Cash Flow Data:

	Nine Months Ended
	April 30,
	2019			2018			Changes ($)
Cash Flows used in Operating Activities	$	(29,578	)	$	(18,424	)	$	(11,154	)
Cash Flows used in Investing Activities	$	-		$	-		$	-
Cash Flows provided by Financing Activities	$	27,000		$	5,000		$	22,000
Net Change in Cash During Period	$	(2,578	)	$	(13,424	)	$	10,846

11

Table of Contents

Cash Flows from Operating Activities

We have not generated positive cash flows from operating activities. For the nine months ended April 30, 2019, net cash flows used in operating activities was $29,578, consisting of a net loss of $24,073, increased by a decrease in accounts payable of $7,999 and reduced by an increase in accrued interest due to related parties of $2,494. For the nine-month period ended April 30, 2018, net cash flows used in operating activities was $18,424, consisting of a net loss of $25,192, decreased by an increase in accounts payable of $5,271 and accrued interest due to related parties of $1,497.

Cash Flows used in Investing Activities

During the nine months ended April 30, 2019 and 2018, no cash flows used in investing activities.

Cash Flows from Financing Activities

We have financed our operations from the issuance of equity and loans from related parties. For the nine months ended April 30, 2019, and 2018, we received $27,000 and $5,000 from financing activities, respectively.

Limited Operating History; Need for Additional Capital

There is no historical financial information about us upon which to base an evaluation of our performance. We are an early stage corporation and have not generated any revenues from operations to fully implement our business plan. We cannot guarantee we will be successful in our business operations. Our business is subject to risks inherent in the establishment of a new business enterprise, including limited capital resources, and competition from larger organizations. We will require equity and/or debt financing to provide for the capital required to implement our plans. We will require additional funds to operate for the next year.

We have no assurance that future financing will be available to us on acceptable terms. If financing is not available on satisfactory terms, we may be unable to continue, develop or expand our operations. Equity financing as envisioned by our Offering will result in additional dilution to existing shareholders.

Liquidity and Capital Resources

From May 20, 2014 (inception) through April 30, 2019, we have relied on funds loaned to us by Kratos Healthcare Inc (“Kratos”), a company controlled by an officer and director, to fund our initial working capital requirements. The current amount due is $80,101 in principal and Kratos has agreed to loan us additional amounts of up to a total of $100,000 (inclusive of cash advances to date).

In the event we are not successful in reaching our initial revenue targets, additional funds may be required, and we may not be able to proceed with our business plan for the development and marketing of our core services. Should this occur, we would likely seek additional financing to support the continued operation of our business. We anticipate that depending on market conditions and our plan of operations, we may incur operating losses in the foreseeable future. Therefore, our auditors have raised substantial doubt about our ability to continue as a going concern.

The controlling shareholders have pledged their support to fund continuing operations during an early stage; however, there is no written commitment to this effect. The Company is dependent upon the continued support.

As of April 30, 2019, we have no employees. Other than our chief financial officer, who we have verbally agreed to pay for management services, our officers and directors are donating their time to the development of our company.

12

Table of Contents

The officers and directors of the Company may be involved in other business activities and may, in the future, become involved in other business opportunities that become available. They may face a conflict in selecting between the Company and other business interests. The Company has not formulated a policy for the resolution of such conflicts.

Contractual Obligations

As a “smaller reporting company”, we are not required to provide tabular disclosure obligations.

Going Concern

As of April 30, 2019, our company had a net loss of $24,073 and has earned no revenues. Our company intends to fund operations through equity financing arrangements, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2019. The ability of our company to emerge from the development stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of our business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings. These factors, among others, raise substantial doubt about our company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our financial statements is critical to an understanding of our financial statements.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements. The estimates and judgments will also affect the reported amounts for certain revenues and expenses during the reporting period. Actual results could differ from these good faith estimates and judgments.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

13

Table of Contents

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of April 30, 2019. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms as a result of the following material weaknesses:

(1) lack of a functioning audit committee, (2) lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; (3) inadequate segregation of duties consistent with control objectives; and (4) management is dominated by two individuals without adequate compensating controls.

A “material weakness” is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the company’s annual or interim financial statements would not be prevented or detected on a timely basis.

We expect to be materially dependent upon a third party to provide us with accounting consulting services for the foreseeable future. Until such time as we have a chief financial officer with the requisite expertise in U.S. GAAP, there are no assurances that the material weaknesses in our disclosure controls and procedures and internal control over financial reporting will not result in errors in our financial statements which could lead to a restatement of those financial statements.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting identified in connection with the evaluation required by paragraph (d) of Securities Exchange Act Rule 13a-15 or Rule 15d-15 that occurred in the quarter ended April 30, 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

14

Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become involved in litigation relating to claims arising out of our operations in the normal course of business. We are not involved in any pending legal proceeding or litigation and, to the best of our knowledge, no governmental authority is contemplating any proceeding to which we are a party and which would reasonably be likely to have a material adverse effect on our company. To date, our company has never been involved in litigation, as either a party or a witness, nor has our company been involved in any legal proceedings commenced by any regulatory agency against our company.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None.

15

Table of Contents

Item 6. Exhibits

The following exhibits are included as part of this report:

Exhibit Number		Description
(3)		Articles of Incorporation and Bylaws
3.1		Articles of Incorporation (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)
3.2		Bylaws (Incorporated by reference to our Registration Statement on Form S-1 filed on September 26, 2014)
(14)		Code of Ethics
14.1		Code of Ethics for Directors, Officers, and Employees (incorporated by reference to exhibit 14.1 in our Registration Statement on Form S-1 filed on September 26, 2014)
14.2		Code of Ethics for CEO And Senior Financial Officers (incorporated by reference to exhibit 14.2 in our Registration Statement on Form S-1 filed on September 26, 2014)
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification by the Principal Executive Officer
31.2*		Section 302 Certification by the Principal Financial Officer and Principal Accounting Officer
(32)		Section 1350 Certifications
32.1**		Section 906 Certification by the Principal Executive Officer
32.2**		Section 906 Certification by the Principal Financial Officer and Principal Accounting Officer
101*		Interactive Data File
101.INS		XBRL Instance Document
101.SCH		XBRL Taxonomy Extension Schema Document
101.CAL		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB		XBRL Taxonomy Extension Label Linkbase Document
101.PRE		XBRL Taxonomy Extension Presentation Linkbase Document

___________

*	Filed herewith.
**	Furnished herewith.

16

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

		PANAMERA HEALTHCARE CORPORATION
		(Registrant)

Dated: June 7, 2019		/s/ Curtis Summers
		Curtis Summers
		President, Chief Executive Officer and Director
		(Principal Executive Officer)

Dated: June 7, 2019		/s/ Douglas G. Baker
		Douglas G. Baker
		Secretary, Chief Financial Officer, Treasurer and Director
		(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 pnht_ex311.htm CERTIFICATION pnht_ex311.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Curtis Summers, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Panamera Healthcare Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 7, 2019

/s/ Curtis Summers
Curtis Summers
President, Chief Executive Officer and Director
(Principal Executive Officer)

EX-31.2 3 pnht_ex312.htm CERTIFICATION pnht_ex312.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas G. Baker, certify that:

1.	I have reviewed this quarterly report on Form 10-Q of Panamera Healthcare Corporation;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.	The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: June 7, 2019

/s/ Douglas G. Baker
Douglas G. Baker
Secretary, Chief Financial Officer, Treasurer and Director
(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 pnht_ex321.htm CERTIFICATION pnht_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Curtis Summers, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Quarterly Report on Form 10-Q of Panamera Healthcare Corporation for the period ended April 30, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Panamera Healthcare Corporation.

Dated: June 7, 2019		/s/ Curtis Summers
		Curtis Summers
		President, Chief Executive Officer and Director (Principal Executive Officer)
		Panamera Healthcare Corporation

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Panamera Healthcare Corporation and will be retained by Panamera Healthcare Corporation and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 pnht_ex322.htm CERTIFICATION pnht_ex322.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas G. Baker, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	the Quarterly Report on Form 10-Q of Panamera Healthcare Corporation for the period ended April 30, 2019 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Panamera Healthcare Corporation.

Dated: June 7, 2019		/s/ Douglas G. Baker
		Douglas G. Baker
		Secretary, Chief Financial Officer, Treasurer and Director (Principal Financial Officer and Principal Accounting Officer)
		Panamera Healthcare Corporation

EX-101.INS 6 pnht-20190430.xml XBRL INSTANCE DOCUMENT 0001620749 pnht:OfficerAndDirectorMember us-gaap:NotesPayableOtherPayablesMember 2014-07-15 0001620749 2017-11-01 2018-01-31 0001620749 2018-07-31 0001620749 2018-11-01 2019-01-31 0001620749 2017-07-31 0001620749 2018-01-31 0001620749 2019-04-30 0001620749 2018-04-30 0001620749 2019-02-01 2019-04-30 0001620749 2018-02-01 2018-04-30 0001620749 2018-08-01 2019-04-30 0001620749 2017-08-01 2018-04-30 0001620749 2019-06-05 0001620749 2018-10-31 0001620749 us-gaap:RetainedEarningsMember 2018-08-01 2018-10-31 0001620749 us-gaap:RetainedEarningsMember 2018-10-31 0001620749 us-gaap:RetainedEarningsMember 2018-07-31 0001620749 us-gaap:CommonStockMember 2018-10-31 0001620749 us-gaap:CommonStockMember 2018-07-31 0001620749 us-gaap:AdditionalPaidInCapitalMember 2018-07-31 0001620749 us-gaap:AdditionalPaidInCapitalMember 2018-10-31 0001620749 us-gaap:RetainedEarningsMember 2018-11-01 2019-01-31 0001620749 us-gaap:CommonStockMember 2019-01-31 0001620749 2019-01-31 0001620749 us-gaap:AdditionalPaidInCapitalMember 2019-01-31 0001620749 us-gaap:RetainedEarningsMember 2019-01-31 0001620749 us-gaap:RetainedEarningsMember 2019-02-01 2019-04-30 0001620749 us-gaap:RetainedEarningsMember 2019-04-30 0001620749 us-gaap:CommonStockMember 2019-04-30 0001620749 us-gaap:AdditionalPaidInCapitalMember 2019-04-30 0001620749 2017-08-01 2017-10-31 0001620749 2017-10-31 0001620749 us-gaap:RetainedEarningsMember 2017-07-31 0001620749 us-gaap:RetainedEarningsMember 2017-08-01 2017-10-31 0001620749 us-gaap:RetainedEarningsMember 2017-10-31 0001620749 us-gaap:RetainedEarningsMember 2017-11-01 2018-01-31 0001620749 us-gaap:RetainedEarningsMember 2018-01-31 0001620749 us-gaap:RetainedEarningsMember 2018-02-01 2018-04-30 0001620749 us-gaap:RetainedEarningsMember 2018-04-30 0001620749 us-gaap:AdditionalPaidInCapitalMember 2017-07-31 0001620749 us-gaap:AdditionalPaidInCapitalMember 2017-10-31 0001620749 us-gaap:AdditionalPaidInCapitalMember 2018-01-31 0001620749 us-gaap:AdditionalPaidInCapitalMember 2018-04-30 0001620749 us-gaap:CommonStockMember 2017-07-31 0001620749 us-gaap:CommonStockMember 2017-10-31 0001620749 us-gaap:CommonStockMember 2018-01-31 0001620749 us-gaap:CommonStockMember 2018-04-30 0001620749 pnht:OfficerAndDirectorMember us-gaap:NotesPayableOtherPayablesMember 2019-04-30 0001620749 pnht:OfficerAndDirectorMember us-gaap:NotesPayableOtherPayablesMember 2018-08-01 2019-04-30 0001620749 pnht:OfficerAndDirectorMember us-gaap:NotesPayableOtherPayablesMember 2017-08-01 2018-04-30 0001620749 2019-04-01 2019-04-15 0001620749 2019-04-15 0001620749 2018-08-01 2018-10-31 shares iso4217:USD iso4217:USD shares pure 0001620749 pnht --07-31 Non-accelerated Filer false 2019 Q3 true true false 10-Q 2019-04-30 PANAMERA HEALTHCARE CORP 17990000

1602

4180

1602

4180

7999

5228

2734

80101

53101

85329

63834

85329

63834

50000000

0.0001

150000000

0.0001

17990000

1799

145750

-231276

-207203

1602

4180

4307

5025

20908

22640

232

336

670

1056

4539

5361

21578

23696

-4539

-5361

-21578

-23696

911

523

2495

1496

-911

-523

-2495

-1496

-5450

-5884

-24073

-25192

-0.00

17990000

1799

145750

-207203

-59654

-12055

17990000

1799

145750

-219258

-71709

-6568

17990000

1799

145750

-225826

-78277

-5450

17990000

1799

145750

-231276

-83727

17990000

1799

145750

-176900

-29351

-12795

17990000

1799

145750

-189695

-42146

-6513

17990000

1799

145750

-196208

-48659

-5884

17990000

1799

145750

-202092

-54543

-24073

-25192

-7999

5271

2494

1497

-29578

-18424

27000

5000

27000

5000

-2578

-13424

4180

13460

1602

<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Basis of Presentation <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the unaudited interim financial statements do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the opinion of management, all adjustments consisting of normal recurring entries necessary for a fair statement of the periods presented for: (a) the financial position; (b) the result of operations; and (c) cash flows, have been made in order to make the unaudited interim financial statements presented not misleading. The results of operations for such interim periods are not necessarily indicative of operations for a full year. The accompanying unaudited interim financial statements should be read in conjunction with the financial statements and related notes included in the Company’s Annual Report on Form 10-K, for the year ended July 31, 2018, as filed with the SEC on October 19, 2018.

<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NOTE 3 - GOING CONCERN <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. As of April 30, 2019, the Company has a loss from operations, an accumulated deficit and has not earned any revenues. The Company intends to fund operations through equity financing arrangements and related party advances, which may be insufficient to fund its capital expenditures, working capital and other cash requirements for the year ending July 31, 2019 <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The ability of the Company to emerge from an early stage is dependent upon, among other things, obtaining additional financing to continue operations, and development of its business plan. In response to these problems, management intends to raise additional funds through public or private placement offerings. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty.

<p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">NOTE 4 - RELATED PARTY TRANSACTIONS <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Note Payable <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On July 15, 2014, a corporation controlled by an officer and director committed $75,000 Promissory Note in the form of an unsecured line of credit. Any unpaid balance was due December 31, 2015. On April 15, 2019, the line of credit increased to $100,000 and was extended to December 31, 2019, at an annual interest rate of 5% and may be prepaid without penalty. The Company concluded the note modification was not a significant change and is not treating it as an extinguishment. During the nine months ended April 30, 2019, the Company borrowed $27,000 and repayments under the line of credit to the Company were made in the amount of $0. As of April 30, 2019, the Company was obligated, for this interest bearing loan with a balance of $80,101 and accrued interest of $5,228. The Company plans to pay the loan and interest back as cash flows become available. The remaining balance available under the line of credit is $19,899 as of April 30, 2019. For the nine months ended April 30, 2019 and 2018, the Company paid $0 and $0, respectively, in interest on this note payable. <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Other <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">  <p align="justify" style="text-align: justify; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0px 0px 0px 0in; font-family: 'times new roman'; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company does not own or lease property or lease office space. The office space used by the Company was arranged by the founder, who is also the CEO and President, of the Company to use at no charge.

75000

100000

0.05

27000

80101

5228

19899

EX-101.SCH 7 pnht-20190430.xsd XBRL TAXONOMY EXTENSION SCHEMA 001 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Statements of Operations (Unaudited) link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Statements Of Changes In Stockholders' Deficit (Unaudited) link:presentationLink link:definitionLink link:calculationLink 006 - Statement - Statements of Cash Flows (Unaudited) link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - GOING CONCERN link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - RELATED PARTY TRANSACTIONS (Detail Textuals) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 pnht-20190430_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pnht-20190430_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pnht-20190430_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Common Stock, Shares Outstanding Common Stock [Member] Common Stock Retained Earnings [Member] Accumulated Deficit Additional Paid-in Capital [Member] Additional Paid-in Capital Line of Credit Facility, Increase (Decrease), Net Shares, Outstanding Balance (in shares) Balance (in shares) Document And Entity Information [Abstract] Entity Registrant Name Entity Central Index Key Trading Symbol Current Fiscal Year End Date Entity Filer Category Document Type Document Period End Date Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Entity Small Business Entity Emerging Growth Company Entity Ex Transition Period Statement of Financial Position [Abstract] Assets [Abstract] ASSETS Assets, Current [Abstract] Current Assets Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Assets, Current Current assets Total Current Assets Assets TOTAL ASSETS Liabilities and Equity [Abstract] LIABILITIES AND STOCKHOLDERS' DEFICIT Liabilities, Current [Abstract] Current Liabilities Accounts Payable and Accrued Liabilities, Current, Total Accounts payable and accrued liabilities Accrued interest - related party Accrued interest - related party Due to Related Parties, Current Due to related party Liabilities, Current Total Current Liabilities Liabilities TOTAL LIABILITIES Stockholders' Equity Attributable to Parent [Abstract] Stockholders' Deficit Preferred Stock, Value, Issued Preferred stock: 50,000,000 authorized; $0.0001 par value no shares issued and outstanding Common Stock, Value, Issued Common stock: 150,000,000 authorized; $0.0001 par value 17,990,000 shares issued and outstanding Additional paid in capital Additional paid in capital Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Stockholders' Equity Attributable to Parent Total Stockholders' Deficit Balance Balance Liabilities and Equity TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT Preferred Stock, Shares Authorized Preferred stock, shares authorized Preferred Stock, Par or Stated Value Per Share Preferred stock, par value (in dollars per share) Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Income Statement [Abstract] Operating Expenses [Abstract] Operating Expenses Professional Fees Professional fees General and Administrative Expense General and administration expenses Operating Expenses Total operating expenses Operating Income (Loss) Loss from operations Net loss from operations Net loss from operations Nonoperating Income (Expense) [Abstract] Other expense Investment Income, Investment Expense Interest expense Interest expense Nonoperating Income (Expense) Total other expense Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest Net loss before taxes Net loss before taxes Income Tax Expense (Benefit) Income tax benefit Income tax expense per books Net Income (Loss) Attributable to Parent Loss from operations Net loss Net loss Earnings Per Share, Basic and Diluted Basic and diluted loss per common share (in dollars per share) Net loss per share, Basic and Diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average number of common shares outstanding, basic and diluted (in shares) Weighted average common shares issued and outstanding (Basic and Diluted) Statement of Cash Flows [Abstract] Net Cash Provided by (Used in) Operating Activities [Abstract] CASH FLOWS FROM OPERATING ACTIVITIES: Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Interest Payable, Net Accrued interest - related party Net Cash Provided by (Used in) Operating Activities, Total Net Cash Used In Operating Activities Net Cash Provided by (Used in) Financing Activities [Abstract] CASH FLOWS FROM FINANCING ACTIVITIES: Proceeds from Related Party Debt Amount borrowed from related party Proceeds from related party loans Net Cash Provided by (Used in) Financing Activities, Total Net Cash Provided by Financing Activities Cash and Cash Equivalents, Period Increase (Decrease) Net change in cash and cash equivalents Supplemental Cash Flow Information [Abstract] Supplemental cash flow information Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for interest Interest paid Income Taxes Paid Cash paid for taxes Organization And Description Of Business [Abstract] Organization And Description Of Business [Text Block] ORGANIZATION AND DESCRIPTION OF BUSINESS The entire disclosure for organization and business description. Accounting Policies [Abstract] Basis of Presentation and Significant Accounting Policies [Text Block] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Going Concern [Abstract] Substantial Doubt about Going Concern [Text Block] GOING CONCERN Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Schedule of Related Party Transactions, by Related Party [Table] Related Party [Axis] Related Party [Domain] Officer And Director [Member] Officer and director Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Notes Payable, Other Payables [Member] Note Payable Related Party Transaction [Line Items] Debt Instrument, Face Amount Promissory note amount Debt Instrument, Interest Rate, Stated Percentage Annual interest rate Repayments of Related Party Debt Net repayments under the line of credit Repayments to related party loans Line of Credit Facility, Remaining Borrowing Capacity Remaining balance available under line of credit Interest Paid Cash paid for interest Interest paid Increase in line of credit Statement of Stockholders' Equity [Abstract] Statement [Table] Equity Component [Domain] Statement [Line Items] Increase (Decrease) in Stockholders' Equity [Roll Forward] Equity Components [Axis] Equity Components [Axis] Statement of Stockholders' Equity [Abstract] EX-101.PRE 11 pnht-20190430_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Apr. 30, 2019	Jun. 05, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	PANAMERA HEALTHCARE CORP
Entity Central Index Key	0001620749
Trading Symbol	pnht
Current Fiscal Year End Date	--07-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		17,990,000
Document Type	10-Q
Document Period End Date	Apr. 30, 2019
Amendment Flag	false
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

XML 13 R2.htm IDEA: XBRL DOCUMENT

Balance Sheets - USD ($)	Apr. 30, 2019	Jul. 31, 2018
Current Assets
Cash and cash equivalents	$ 1,602	$ 4,180
Total Current Assets	1,602	4,180
TOTAL ASSETS	1,602	4,180
Current Liabilities
Accounts payable and accrued liabilities		7,999
Accrued interest - related party	5,228	2,734
Due to related party	80,101	53,101
Total Current Liabilities	85,329	63,834
TOTAL LIABILITIES	85,329	63,834
Stockholders' Deficit
Preferred stock: 50,000,000 authorized; $0.0001 par value no shares issued and outstanding	0	0
Common stock: 150,000,000 authorized; $0.0001 par value 17,990,000 shares issued and outstanding	1,799	1,799
Additional paid in capital	145,750	145,750
Accumulated deficit	(231,276)	(207,203)
Total Stockholders' Deficit	(83,727)	(59,654)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 1,602	$ 4,180

XML 14 R3.htm IDEA: XBRL DOCUMENT

Balance Sheets (Parentheticals) - $ / shares	Apr. 30, 2019	Jul. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	150,000,000	150,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares issued	17,990,000	17,990,000
Common stock, shares outstanding	17,990,000	17,990,000

XML 15 R4.htm IDEA: XBRL DOCUMENT

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Apr. 30, 2019	Apr. 30, 2018	Apr. 30, 2019	Apr. 30, 2018
Operating Expenses
Professional fees	$ 4,307	$ 5,025	$ 20,908	$ 22,640
General and administration expenses	232	336	670	1,056
Total operating expenses	4,539	5,361	21,578	23,696
Net loss from operations	(4,539)	(5,361)	(21,578)	(23,696)
Other expense
Interest expense	(911)	(523)	(2,495)	(1,496)
Total other expense	(911)	(523)	(2,495)	(1,496)
Net loss before taxes	(5,450)	(5,884)	(24,073)	(25,192)
Income tax benefit	0	0	0	0
Net loss	$ (5,450)	$ (5,884)	$ (24,073)	$ (25,192)
Basic and diluted loss per common share (in dollars per share)	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
Weighted average number of common shares outstanding, basic and diluted (in shares)	17,990,000	17,990,000	17,990,000	17,990,000

XML 16 R5.htm IDEA: XBRL DOCUMENT

Statements Of Changes In Stockholders' Deficit (Unaudited) - USD ($)	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Total
Balance at Jul. 31, 2017	$ 1,799	$ 145,750	$ (176,900)	$ (29,351)
Balance (in shares) at Jul. 31, 2017	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(12,795)	(12,795)
Balance at Oct. 31, 2017	$ 1,799	145,750	(189,695)	(42,146)
Balance (in shares) at Oct. 31, 2017	17,990,000
Balance at Jul. 31, 2017	$ 1,799	145,750	(176,900)	(29,351)
Balance (in shares) at Jul. 31, 2017	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss				(25,192)
Balance at Apr. 30, 2018	$ 1,799	145,750	(202,092)	(54,543)
Balance (in shares) at Apr. 30, 2018	17,990,000
Balance at Oct. 31, 2017	$ 1,799	145,750	(189,695)	(42,146)
Balance (in shares) at Oct. 31, 2017	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(6,513)	(6,513)
Balance at Jan. 31, 2018	$ 1,799	145,750	(196,208)	(48,659)
Balance (in shares) at Jan. 31, 2018	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(5,884)	(5,884)
Balance at Apr. 30, 2018	$ 1,799	145,750	(202,092)	(54,543)
Balance (in shares) at Apr. 30, 2018	17,990,000
Balance at Jul. 31, 2018	$ 1,799	145,750	(207,203)	(59,654)
Balance (in shares) at Jul. 31, 2018	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(12,055)	(12,055)
Balance at Oct. 31, 2018	$ 1,799	145,750	(219,258)	(71,709)
Balance (in shares) at Oct. 31, 2018	17,990,000
Balance at Jul. 31, 2018	$ 1,799	145,750	(207,203)	(59,654)
Balance (in shares) at Jul. 31, 2018	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss				(24,073)
Balance at Apr. 30, 2019	$ 1,799	145,750	(231,276)	(83,727)
Balance (in shares) at Apr. 30, 2019	17,990,000
Balance at Oct. 31, 2018	$ 1,799	145,750	(219,258)	(71,709)
Balance (in shares) at Oct. 31, 2018	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(6,568)	(6,568)
Balance at Jan. 31, 2019	$ 1,799	145,750	(225,826)	(78,277)
Balance (in shares) at Jan. 31, 2019	17,990,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss			(5,450)	(5,450)
Balance at Apr. 30, 2019	$ 1,799	$ 145,750	$ (231,276)	$ (83,727)
Balance (in shares) at Apr. 30, 2019	17,990,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Apr. 30, 2019	Apr. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (24,073)	$ (25,192)
Changes in operating assets and liabilities:
Accounts payable	(7,999)	5,271
Accrued interest - related party	2,494	1,497
Net Cash Used In Operating Activities	(29,578)	(18,424)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from related party loans	27,000	5,000
Net Cash Provided by Financing Activities	27,000	5,000
Net change in cash and cash equivalents	(2,578)	(13,424)
Cash and cash equivalents, beginning of period	4,180	13,460
Cash and cash equivalents, end of period	1,602	36
Supplemental cash flow information
Cash paid for interest	0	0
Cash paid for taxes	$ 0	$ 0

XML 18 R7.htm IDEA: XBRL DOCUMENT

ORGANIZATION AND DESCRIPTION OF BUSINESS

9 Months Ended

Apr. 30, 2019

Organization And Description Of Business [Abstract]

ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 - ORGANIZATION AND DESCRIPTION OF BUSINESS

XML 19 R8.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

XML 20 R9.htm IDEA: XBRL DOCUMENT

GOING CONCERN

9 Months Ended

Apr. 30, 2019

Going Concern [Abstract]

GOING CONCERN

NOTE 3 - GOING CONCERN

XML 21 R10.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS

9 Months Ended

Apr. 30, 2019

RELATED PARTY TRANSACTIONS

NOTE 4 - RELATED PARTY TRANSACTIONS

Note Payable

Other

XML 22 R11.htm IDEA: XBRL DOCUMENT

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Apr. 30, 2019

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

XML 23 R12.htm IDEA: XBRL DOCUMENT

RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)	1 Months Ended	9 Months Ended
RELATED PARTY TRANSACTIONS (Detail Textuals) - USD ($)	Apr. 15, 2019	Apr. 30, 2019	Apr. 30, 2018	Jul. 31, 2018	Jul. 15, 2014
Related Party Transaction [Line Items]
Increase in line of credit	$ 100,000
Annual interest rate	5.00%
Amount borrowed from related party		$ 27,000	$ 5,000
Due to related party		80,101		$ 53,101
Accrued interest - related party		5,228		$ 2,734
Officer and director \| Note Payable
Related Party Transaction [Line Items]
Promissory note amount					$ 75,000
Amount borrowed from related party		27,000
Net repayments under the line of credit		0
Due to related party		80,101
Accrued interest - related party		5,228
Remaining balance available under line of credit		19,899
Cash paid for interest		$ 0	$ 0

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end

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the quarterly period ended April 30, 2019

or

¨	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from _____________ to _____________